Skip to content
PubMed This is a summary of 11 peer-reviewed journal articles Updated
Gynecology · Atypical Polypoid Adenomyoma

Treatment Strategies & Fertility Preservation for APA

At a Glance

For atypical polypoid adenomyoma, fertility-sparing care usually centers on complete hysteroscopic removal followed by repeat biopsies and hysteroscopies every 3 to 6 months. Hysterectomy may be recommended for persistent, recurrent, deep, or cancer-associated disease.

Choosing a treatment for atypical polypoid adenomyoma (APA) depends heavily on your goals for the future, particularly whether you wish to preserve your fertility. Because APA is so rare, there are no “universal” guidelines like those for more common cancers; instead, doctors rely on expert consensus and findings from small groups of patients [1][2].

The Treatment Decision Tree

Your care team will generally recommend a path based on your age and family planning goals:

  • Fertility-Sparing Path: For women who want to become pregnant, the goal is to remove the lesion completely while keeping the uterus healthy [1][2].
  • Definitive Path: For women who have finished childbearing or are postmenopausal, a hysterectomy (removal of the uterus) is often recommended because it is a definitive option that removes the uterine site where the disease occurs [1][3].

Fertility-Sparing: Hysteroscopic Resection

A preferred way to treat APA while preserving fertility is a procedure called transcervical resection (TCR). During this procedure, a surgeon uses a small camera (hysteroscope) and specialized tools to precisely cut out the growth [1].

Research highlights a specific technique known as the four-step resection as a commonly used approach by experienced surgeons [1]. While the exact steps may vary by surgeon, this methodical approach focuses on:

  1. Removing the visible portion of the polyp.
  2. Excising the “base” where the growth meets the uterine wall.
  3. Sampling the muscle tissue underneath the lesion (myometrium) to evaluate for deep cells.
  4. Sampling the surrounding uterine lining (endometrium) to check for hidden precancerous cells [1][4].

This guided approach is generally favored over “blind” procedures like a D&C. Studies show that patients who have a guided hysteroscopic resection have lower rates of cancer progression and fewer recurrences than those who have blind curettage, though it is not a guaranteed cure [2][1].

The Role of Hormone Therapy

Doctors sometimes use progestins (synthetic versions of the hormone progesterone) as an adjunct to help treat APA or prevent it from coming back. These can be given as a pill (like medroxyprogesterone acetate or MPA) or via a hormonal IUD (like the LNG-IUS) [5][6].

However, the evidence for hormone therapy in APA is mixed and limited:

  • Initial Response: Some patients show an initial histologic response to progestins [5].
  • Risk of Return: Even with hormone therapy, APA has a high rate of coming back (recurrence). In one study, many patients showed a response to medication, but others later experienced persistent disease or eventually needed a hysterectomy [5].
  • Adjuvant Use: Some doctors prescribe progestins after surgery as an adjunct, though not all studies agree this provides a clear reduction in recurrence, and side effects should be individually considered [4][7].

When Hysterectomy is Recommended

While the goal for many is to save the uterus, a hysterectomy may be a definitive option in certain scenarios. It comes with major consequences, including permanent loss of the ability to carry a pregnancy, surgical risks, and a decision on whether to remove the ovaries.

  • No Desire for Fertility: If you do not plan to have children, a hysterectomy is a definitive choice for preventing recurrence [1][8].
  • Concurrent Disease: If your pathology shows that endometrial cancer or atypical hyperplasia (EIN) is present alongside the APA, definitive surgery is often recommended [7][9].
  • Persistent or Recurring Disease: If the APA returns after multiple resections, the risk of it eventually turning into cancer increases, making surgery a safer long-term choice [10][11].
  • Technical Challenges: If the growth is very deep in the uterine muscle wall, it may be impossible to remove safely via hysteroscopy without risking a hole in the uterus (perforation) [6].

Life After Treatment

If you choose the fertility-sparing path, treatment is not a “one-and-done” event. You will enter a phase of active surveillance. This typically involves repeat hysteroscopies and biopsies every 3 to 6 months to ensure the area stays clear [1][4]. For those who wish to conceive, the timing of attempting pregnancy should involve individualized planning with your gynecologic surgeon and a reproductive endocrinologist [10].

Common questions in this guide

What is the usual fertility-sparing treatment for APA?
The main fertility-sparing approach is a guided hysteroscopic resection, also called transcervical resection. The surgeon removes the visible lesion and its base, then samples nearby uterine muscle and lining to look for deeper or hidden abnormal cells. Follow-up hysteroscopies and biopsies are usually needed.
Why is a four-step resection used for atypical polypoid adenomyoma?
The four-step approach systematically removes the visible polyp, the tissue where it attaches, and samples the underlying muscle and surrounding uterine lining. This can help the team assess whether abnormal cells extend deeper or beyond what can be seen. A trained surgeon may adapt the steps to your anatomy.
Can progestin therapy prevent APA from returning?
Progestins, such as oral medroxyprogesterone acetate or a levonorgestrel-releasing IUD, are sometimes used after surgery or in selected patients. Some patients respond at first, but evidence is limited and mixed, and the lesion can still persist or recur. Your clinician should discuss expected benefits, side effects, and alternatives.
When might hysterectomy be recommended for APA?
Hysterectomy may be considered when future pregnancy is not desired, after menopause, or when APA persists or returns after repeated treatment. It is also often recommended when endometrial cancer or atypical hyperplasia is found, or when the lesion is too deep to remove safely through the cervix. It permanently prevents carrying a pregnancy and has surgical risks.
How often will I need follow-up after fertility-sparing APA treatment?
Follow-up commonly includes a hysteroscopy and biopsy every 3 to 6 months, although your schedule depends on pathology and treatment response. Ongoing surveillance is important because APA can recur even after the lesion is removed. Pregnancy planning should be individualized with a gynecologic surgeon and reproductive endocrinologist.
Can I become pregnant after fertility-sparing APA treatment?
Fertility-sparing treatment is intended to preserve the uterus and the possibility of carrying a pregnancy, but it does not guarantee pregnancy or prevent recurrence. The timing of trying to conceive should be planned after treatment and follow-up with your gynecologic surgeon and a reproductive endocrinologist. They can tailor the plan to your pathology and surveillance results.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Can you perform the 'four-step' hysteroscopic resection, and how do you ensure the base of the lesion is completely removed?
  2. 2.What was the 'margin' status of my biopsy? Did the pathologist find any cancer or EIN in the tissue surrounding the APA?
  3. 3.If we choose fertility-sparing treatment, what is my exact schedule for follow-up biopsies and hysteroscopies?
  4. 4.Given my specific pathology, do you recommend adding progestin therapy (like an IUD or oral pills) after my surgery?
  5. 5.Are there any signs on my MRI or ultrasound that the growth goes deep into the muscle wall, which might make hysteroscopy more risky?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (11)
  1. 1

    Management of women with atypical polypoid adenomyoma of the uterus: A quantitative systematic review.

    Raffone A, Travaglino A, Saccone G, et al.

    Acta obstetricia et gynecologica Scandinavica 2019; (98(7)):842-855 doi:10.1111/aogs.13553.

    PMID: 30714089
  2. 2

    Atypical polypoid adenomyoma follow-up and management: Systematic review of case reports and series and meta-analysis.

    Biasioli A, Londero AP, Orsaria M, et al.

    Medicine 2020; (99(26)):e20491 doi:10.1097/MD.0000000000020491.

    PMID: 32590732
  3. 3

    Management of atypical polypoid adenomyoma of the uterus: A single center's experience.

    Ma B, Zhu Y, Liu Y

    Medicine 2018; (97(12)):e0135 doi:10.1097/MD.0000000000010135.

    PMID: 29561413
  4. 4

    Oncologic outcomes of conservative treatment of atypical polypoid adenomyoma of the uterus: A two-center experience.

    Casadio P, Raffone A, Travaglino A, et al.

    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2022; (159(1)):79-85 doi:10.1002/ijgo.14077.

    PMID: 34921691
  5. 5

    Long-term outcomes of fertility-sparing treatment of atypical polypoid adenomyoma with medroxyprogesterone acetate.

    Nomura H, Sugiyama Y, Tanigawa T, et al.

    Archives of gynecology and obstetrics 2016; (293(1)):177-181 doi:10.1007/s00404-015-3824-9.

    PMID: 26209972
  6. 6

    Successful laparotomy tumor resection and levonorgestrel-releasing intrauterine system for atypical polypoid adenomyoma.

    Narumi R, Takei Y, Morisawa H, et al.

    The journal of obstetrics and gynaecology research 2019; (45(1)):230-234 doi:10.1111/jog.13783.

    PMID: 30094884
  7. 7

    A Clinicopathological Review of 203 Cases of Atypical Polypoid Adenomyoma of the Uterus.

    Sun Y, Tian L, Liu G

    Journal of clinical medicine 2023; (12(4)) doi:10.3390/jcm12041511.

    PMID: 36836047
  8. 8

    Clinical presentation and management of atypical polypoid adenomyomas: Systematic review of the literature.

    Mikos T, Tsolakidis D, Grimbizis GF

    European journal of obstetrics, gynecology, and reproductive biology 2019; (236()):14-21 doi:10.1016/j.ejogrb.2019.02.027.

    PMID: 30875539
  9. 9

    Clinical analysis of 44 cases of atypical polypoid adenomyoma of the uterus.

    Wang X, Guo Y

    BMC women's health 2022; (22(1)):60 doi:10.1186/s12905-022-01643-y.

    PMID: 35246106
  10. 10

    Hysteroscopic Transcervical Resection for Atypical Polypoid Adenomyoma of the Uterus: A Valid, Fertility-Preserving Option.

    Chiyoda T, Lin BL, Saotome K, et al.

    Journal of minimally invasive gynecology 2018; (25(1)):163-169.e1 doi:10.1016/j.jmig.2017.08.659.

    PMID: 29038039
  11. 11

    Pregnant outcomes of atypical polypoid adenomyoma treated with progestin therapy.

    Chen Q, Lu W, Lu B

    The journal of obstetrics and gynaecology research 2018; (44(2)):323-330 doi:10.1111/jog.13527.

    PMID: 29121416

This page is for informational purposes only and does not constitute medical advice about atypical polypoid adenomyoma. Your gynecologic surgeon and fertility specialist can interpret your pathology and help you weigh treatment and pregnancy plans.

Get notified when new evidence is published on uterine corpus atypical polypoid adenomyoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.